Adding Daratumumab to VMP for Transplant-Ineligible Myeloma: Maria Victoria Mateos, MD, PhD

Over half of patients with newly diagnosed multiple myeloma (NDMM) are ineligible for autologous stem cell transplantation. For these patients, a combination therapy consisting of the proteasome inhibitor bortezomib with melphalan and prednisone is one of the preferred treatments. Adding daratumumab to standard regimens for transplant-ineligible NDMM and relapsed/refractory multiple myeloma has had promising results. Now, data from the phase 3 ALCYONE trial show that adding daratumumab to bortez...
Continue reading

Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes, a gram-positive bacterium to which individuals with weakened immune systems are susceptible.Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an important ...
Continue reading

Transplant-Ineligible Myeloma: Adding Daratumumab to VMP Increases Survival

Adding daratumumab to bortezomib/melphalan/prednisone (VMP) increases overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), according to results of the phase 3 ALCYONE trial to be presented in December at the American Society of Hematology (ASH) Annual Meeting and Exposition.Patients who are ineligible for autologous stem cell transplantation comprise approximately half of NDMM patients, and the combination of bortezomib, a proteasome inhibitor, with me...
Continue reading

Daratumumab FDA Approved for Transplant-Eligible Patients With Multiple Myeloma

The FDA has now approved daratumumab (Darzalex®, Janssen) to be used in combination with bortezomib, thalidomide, and dexamethasone (VTd) in adult patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.Daratumumab, a targeted monoclonal antibody, works by attaching itself to a protein called CD38 on multiple myeloma cells. This either directly kills the multiple myeloma cells or allows the body to identify these cells as a foreign invader, therefor...
Continue reading

New Daratumumab Combination Approved in Multiple Myeloma

The FDA has now approved daratumumab (Darzalex®, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).The approval was based on MAIA (NCT02252172), an open-label, active-controlled phase 3 trial that randomized 737 ASCT-ineligible patients with newly diagnosed multiple myeloma to receive either daratumumab plus lenalidomide/dexamethasone or lenalidomide/...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.